Dec 07, 2006, 01.25 PM IST | Source:

Granules India signs MoU with PharmaMatch

Granules India signs MOU with PharmaMatch

PharmaMatch B.V. and Granules India Limited are pleased to announce the signing of a Memorandum of Understanding to develop, manufacture and market formulations in the European Market jointly. 


This arrangement will kick-off with the transfer of existing marketing authorizations by PharmaMatch to Granules for products like Paracetamol where Granules has the basic and the necessary skill sets to deliver the same.  This will use the upcoming finished dosage facility of Granules which is expected to be commissioned and fully operational by May 2007.


Commenting on the development, Mr. Irfan Vazirally, Executive Director, PharmaMatch India, said, “Granules has demonstrated excellent capabilities in pharmaceutical manufacturing and they are counting on their capabilities to take this forward in their new business of finished dosages as well”.


Mr. C. Krishna Prasad, Managing Director, Granules India Ltd. said, “PharmaMatch is a renowned finished dosage player in European Union and we expect this relationship to catapult Granules strongly into the European Market. We are expecting this development to expedite the approval process for the finished dosage facility in the European Union”. 


Sourced From: Adfactors Public Relations Pvt Ltd

Granules India stock price

On July 01, 2015, Granules India closed at Rs 83.95, down Rs 0.7, or 0.83 percent. The 52-week high of the share was Rs 1017.10 and the 52-week low was Rs 75.20.

The company's trailing 12-month (TTM) EPS was at Rs 4.94 per share as per the quarter ended March 2015. The stock's price-to-earnings (P/E) ratio was 16.99. The latest book value of the company is Rs 16.81 per share. At current value, the price-to-book value of the company is 4.99.

Set email alert for


video of the day

Short-term players, beware of Greece: Religare Invesco MF

Explore Moneycontrol

Copyright © Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of is prohibited.